GO
Loading...

Biotech and Pharmaceuticals

More

  • Catamaran leads Nasdaq   Monday, 30 Mar 2015 | 1:00 PM ET
    Catamaran leads Nasdaq

    CNBC's Bertha Coombs reports on healthcare stock deals including Catamaran to be acquired by UnitedHealth for $12.8B.

  • Dinan's stocks: KRFT, SJM & MCD   Monday, 30 Mar 2015 | 12:27 PM ET
    Dinan's stocks: KRFT, SJM & MCD

    Jamie Dinan, York Capital founder and CEO, discusses some of his firm's top stock picks. Among the names, he likes the Kraft Foods Group-Heinz deal, as well as McDonald's, which he says is now in the "show me" category.

  • Dinan: Shorting IBB can be dangerous   Monday, 30 Mar 2015 | 12:25 PM ET
    Dinan: Shorting IBB can be dangerous

    Jamie Dinan, York Capital founder and CEO, discusses the advancements in biotechnology, and high stock valuations. He says shorting the biotech ETF can be dangerous.

  • Teva to buy Auspex for $3.2 billion in cash   Monday, 30 Mar 2015 | 7:01 AM ET
    Teva to buy Auspex for $3.2 billion in cash

    Teva Pharmaceutical is buying Auspex Pharmaceuticals, reports CNBC's Joe Kernen.

  • Genfit sinks 31%, but CEO defends liver drug results Friday, 27 Mar 2015 | 3:30 PM ET
    A researcher works in a laboratory of French biopharmaceutical company Genfit, in Loos, northern France, Nov. 15, 2012.

    The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.

  • Drug trial setbacks   Friday, 27 Mar 2015 | 2:20 PM ET
    Drug trial setbacks

    After speaking with the Genfit CEO, CNBC's Meg Tirrell discusses the company's future and the potential opportunity.

  • This sector may get whacked as short interest rises Friday, 27 Mar 2015 | 8:16 AM ET
    Biotech

    A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a year.

  • Biotech woes: Deja vu all over again Thursday, 26 Mar 2015 | 12:59 PM ET
    Biotech

    For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.

  • Biotech outlook dire as bull market loses leader Thursday, 26 Mar 2015 | 8:10 AM ET
    Biotech research

    Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.

  • Biotech a little 'over its skis' but healthy: Analyst

    Eric Schmidt, Cowen & Company analyst, provides perspective on the biotech space after the Nasdaq biotech index posted its worst daily drop since December.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • Trading the selloff: 8 stocks to buy Wednesday, 25 Mar 2015 | 6:50 PM ET
    A file photo of a FedEx truck

    "Fast Money" traders discussed how to play Wednesday's selloff in biotech, transportation and technology names.

  • Time to bet big against Nasdaq? Wednesday, 25 Mar 2015 | 2:52 PM ET
    Janet Yellen speaks in Washington March 18, 2015.

    Janet Yellen may be right … about eight months late though.

  • Hottest dividend stocks of 2015 Tuesday, 24 Mar 2015 | 2:58 PM ET
    A trader works on the floor of the New York Stock Exchange.

    CNBC screened the large cap S&P 500 index to see where the hottest parts of the dividend stock market have been.

  • Here's how to protect your profits in biotech: Trader

    Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.

  • Biogen downgrade, Pfizer rises   Monday, 23 Mar 2015 | 2:14 PM ET
    Biogen downgrade, Pfizer rises

    CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.

  • Biotech's path to discovery: BioMarin CEO   Monday, 23 Mar 2015 | 8:33 AM ET
    Biotech's path to discovery: BioMarin CEO

    Jean-Jacques Bienaime, BioMarin Pharmaceuticals CEO, discusses his company's bull run and new drugs to treat rare diseases, including Duchenne muscular dystrophy.

  • Biogen takes aim at Alzheimer's, ALS drugs Monday, 23 Mar 2015 | 6:48 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • Biotech bulls take charge   Friday, 20 Mar 2015 | 4:27 PM ET
    Biotech bulls take charge

    Why the biotech space still has room to run, with John Stoltzfus, Oppeneimer, and the "Closing Bell" panel.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.